Made With Uberflip Content Marketing

Erin Righetti

Editor-in-Chief, Insight

  • BIO-Europe Spring 2017 kicks off this week in Barcelona

    BIO-Europe Spring 2017 kicks off this week in Barcelona

    Read
  • BIO-Europe Spring 2017 kicks off this week in Barcelona

    BIO-Europe Spring 2017 kicks off this week in Barcelona

    BIO-Europe Spring® international partnering conference kicked off yesterday in Barcelona with an estimated 2,500 attendees representing executives from the life sciences, including nearly 200...

    Read
  • World RARE Disease Day shines a light on rare disease community

    World RARE Disease Day shines a light on rare disease community

    Tomorrow is the 10th annual World RARE Disease Day. Various activities are taking place all over the United States as well as countless locations around the world. World RARE Disease Day is an...

    Read
  • Barcelona biotech companies shine light on regional entrepreneurship

    Barcelona biotech companies shine light on regional entrepreneurship

    Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....

    Read
  • What’s the deal with Immuno-oncology partnering?

    What’s the deal with Immuno-oncology partnering?

    Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...

    Read
  • Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to...

    Read
  • Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development. Read...

    Read
  • Rare diseases, rare commitment

    Rare diseases, rare commitment

    Patients, their families and patient foundations are invaluable in helping drug developers understand the day-to-day realities of approx. 7,000 rare diseases (of which only 400 have therapies)....

    Read
  • The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The number of cell therapies in clinical trials has grown 21 percent since 2015, with more than 759 trials underway globally. With that growth it is time for the industry to get serious about...

    Read
  • UK Establishment upbeat about Brexit’s effect on British life science industry

    UK Establishment upbeat about Brexit’s effect on British life science industry

    Brexit may no longer be at the top of popular news, but it continues to be a key concern for biopharma companies in post-Brexit 2017. The sentiment of key players from the UK life sciences from a...

    Read
  • Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Guest blog post by Murray Aitken, Executive Director of the QuintilesIMS Institute Adequate returns on life sciences investments underpin the sustainability of the innovation lifecycle.   And...

    Read
  • How Do Healthcare Investors and Payers Separate the Tools From the Toys?

    How Do Healthcare Investors and Payers Separate the Tools From the Toys?

      Guest post by Nicole Fisher, Founder & CEO at HHR Strategies, Inc., Forbes Contributor The healthcare sector does not behave like other industries when it comes to money. First, attracting...

    Read
  • Industry pundit Joe Hage on medtech innovation in 2017

    Industry pundit Joe Hage on medtech innovation in 2017

    Joe Hage, a medical device marketing consultant, is well known in medtech circles. In particular, he runs one of the largest and possibly most successful LinkedIn groups, the “Medical Devices...

    Read
  • BIO-Europe® 2016 recap from day one

    BIO-Europe® 2016 recap from day one

    It was the best of times, it was the worst of times. This was the biotech industry in 2016. While this year marked yet another blockbuster year for dealmaking where larger pharma companies scooped...

    Read
  • A snapshot of hot biotech in Latin America

    A snapshot of hot biotech in Latin America

    According to a report from Deloitte, healthcare spending in Latin America is projected to increase 4.6 percent on average annually between 2014 and 2018, as pharmaceutical spending grows an...

    Read
  • Puerto Rico poised to tackle development of a HIV-AIDS vaccine

    Puerto Rico poised to tackle development of a HIV-AIDS vaccine

    Read
  • Are your business development skills getting you the results you want?

    Are your business development skills getting you the results you want?

    Companies value executives who can think on their feet, and not only conceive of winning strategies, but execute on those strategies, according to a recent Harvard Business Review article.  ...

    Read
  • Protecting your IP: Checklist

    Protecting your IP: Checklist

    In biotechnology you cannot get very far without solid IP. For a startup company, having a solid IP strategy is an essential requirement to maximizing value. Muna Abu-Shaar, PhD, Founder of...

    Read
  • Top tips from investors on pitching your company from BioPharm America™ 2016

    Top tips from investors on pitching your company from BioPharm America™ 2016

    A group of seasoned biotech investors gathered this week at BioPharm America™ to meet with innovative biotech companies, and to participate in “The Perfect Pitch: Do you have what it takes to win...

    Read
  • Report reveals critical role of partnering for future big pharma pipelines

    Report reveals critical role of partnering for future big pharma pipelines

    A close look at projected changes in the Top 10 drugs by revenue between 2015 and 2023 reveals a significant downward trend in combined revenue. From 2015 to 2023 the combined revenue of the...

    Read
  • loading
    Loading More...